Bennett Lawrence Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Bennett Lawrence Management’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	$2.66M	Sell	13,955 -2,720	-16%	-$475K	0.86%	45
2015 Q3	$2.61M	Sell	16,675 -6,625	-28%	-$1.21M	0.83%	47
2015 Q2	$4.21M	Sell	23,300 -70	-0.3%	-$12.1K	1.11%	34
2015 Q1	$4.05M	Sell	23,370 -1,205	-5%	-$218K	1.08%	36
2014 Q4	$4.55M	Buy	24,575 +8,174	+50%	+$1.51M	1.23%	36
2014 Q3	$2.72M	Hold	16,401	–	–	0.62%	57
2014 Q2	$2.56M	Sell	16,401 -6,120	-27%	-$966K	0.45%	65
2014 Q1	$3.43M	Sell	22,521 -670	-3%	-$107K	0.51%	59
2013 Q4	$3.08M	Sell	23,191 -24,864	-52%	-$2.98M	0.47%	59
2013 Q3	$5.58M	Buy	+48,055	New	+$5.27M	0.9%	50

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bennett Lawrence Management's ALXN Position: Q4 2015 in Review

Bennett Lawrence Management reduced its Alexion Pharmaceuticals (ALXN) stake by 16% in Q4 2015, selling an estimated $475K and leaving 13,955 shares worth $2.66M. The position accounts for 0.86% of the portfolio, ranked #45.

Bennett Lawrence Management first reported a position in ALXN in Q3 2013 and has held it in 10 quarters since. The position peaked at $5.58M in Q3 2013. 548 funds tracked by Wall St. Rank hold ALXN as of Q4 2015.

Bennett Lawrence Management held 13,955 shares of Alexion Pharmaceuticals worth $2.66M as of Q4 2015.
Bennett Lawrence Management sold 2,720 Alexion Pharmaceuticals shares in Q4 2015, an estimated $475K.
Alexion Pharmaceuticals made up 0.86% of Bennett Lawrence Management's portfolio in Q4 2015, its #45 holding.
Bennett Lawrence Management first reported a position in Alexion Pharmaceuticals in Q3 2013 and has held it in 10 quarters since.
Bennett Lawrence Management's Alexion Pharmaceuticals position peaked at $5.58M in Q3 2013.
548 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2015.

Based on Bennett Lawrence Management's 13F filing for Q4 2015, filed 16 Feb 2016.